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Rapamycin, a potent immunosuppressant used in renal
transplantation, has been reported to impair longitudinal
growth in experimental studies. Rapamycin is both
antiproliferative and antiangiogenic; therefore, it has the
potential to disrupt vascular endothelial growth factor (VEGF)
action in the growth plate and to interfere with insulin-like
growth factor I (IGF-I) signaling. To further investigate the
mechanisms of rapamycin action on longitudinal growth, we
gave the 4-week-old rats rapamycin daily for two weeks.
Compared with a vehicle-treated group, rapamycin-treated
animals were severely growth retarded and had marked
alterations in the growth plate. Vascular invasion was
disturbed in the rapamycin group, there was a significant
reduction in osteoclast cells near the chondro-osseus
junction, and there was lower VEGF protein and mRNA
expression in the terminal chondrocytes of the growth
cartilage. Compared with the control group, the rapamycin
group had higher levels of circulating IGF-I as well as the
mRNAs for IGF-I and of the receptors of IGF-I and growth
hormone in the liver but not in the growth cartilage. Thus our
findings explain the adverse effect of rapamycin on growth
plate dynamics. This should be taken into account when
the drug is administered to children.
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Rapamycin (Rapamune, Wyeth Pharmaceuticals, Philadelphia,
PA, USA) has been widely used as an immunosuppressant for
the treatment of renal transplanted patients.1 Early studies
reported that rapamycin (LC Laboratories, Woburn, MA,
USA), alone or in combination with calcineurin inhibitors,
improved renal function2,3 and decreased the risk of
developing tumors in transplanted patients.4,5 In addition,
mammalian target of rapamycin (mTOR) inhibitors, such as
rapamycin and its derivatives (rapalogs), proved to be
effective against various proliferative disorders6–8 mainly
because they exhibit both antiproliferative9 and antiangio-
genic10 activities. However, rapamycin therapy should be
restricted to very particular conditions because of the risk of
severe side effects, including increases in serum cholesterol
and triglycerides, anemia, proteinuria, skin rashes, and
diarrhea.11
In pediatric patients, rapamycin is mainly used as a
substitute for calcineurin inhibitors when nephrotoxicity or
proliferative diseases occur.12 One of the main challenges in
the management of children with chronic disorders is to
preserve the linear growth and rapamycin has the potential to
interfere with longitudinal growth. Recent studies have
shown that rapamycin administration impairs longitudinal
growth in fast-growing rats,13,14 and local infusion of
rapamycin directly into the proximal tibial growth plates of
rabbits has also been shown to inhibit overall long bone
growth.15 Longitudinal growth is the result of new bone
formation during endochondral ossification, in which
proliferation and differentiation of epiphyseal growth plate
chondrocytes directly correlate with bone elongation. We13
and others14,15 have reported the adverse effects on
chondrocyte proliferation and maturation in rapamycin-
treated animals, which eventually resulted in a reduction of
longitudinal growth velocity.
mTOR is a major regulator of cell growth and energetic
metabolism,16 acting downstream of growth factors as insulin
and insulin-like growth factors (IGFs).9 mTOR inhibition by
rapamycin has been reported to partially block IGF-I
intracellular signaling and its subsequent effects.17–19 Besides
growth hormone (GH), IGF-I has a key role in bone
elongation, and both systemic and local alterations
of GH–IGF-I axis are associated with severe growth
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retardation.20 Therefore, inhibition of IGF-I signaling by
rapamycin could affect longitudinal growth, however, this
hypothesis has not been so far addressed.
Vascular invasion of the growth cartilage is another essential
process for physiological bone formation during endochondral
ossification. Vascular endothelial growth factor A (VEGF) has
a key role in the vascular invasion of the growth cartilage, and
its inactivation results in a considerable expansion of the
hypertrophic zone of the growth plate and disrupts the normal
vascular pattern of the growth plate in young mice.21 Guba
et al.10 reported that in tumoral tissues, the antiangiogenic
activity of rapamycin was linked to a decrease in VEGF
production and to an inhibited response of vascular
endothelial cells to VEGF stimulation. Additional experimental
evidence support the adverse effect of rapamycin on VEGF, not
only on mRNA synthesis,22 but also on protein production
and secretion.23–25 The tibial growth plate of rats with growth
retardation induced by rapamycin exhibit morphological
abnormalities indicative of severe disturbance of the vascular
invasion process as well as expansion of the hypertrophic zone,
similar to that observed in VEGF inactivated mice, and
decreased VEGF immunohistochemical signal.13,14,21
Although there are strong experimental evidence that
rapamycin impairs longitudinal growth, its mechanisms of
action remain to be elucidated. On the basis of the hypothesis
that rapamycin can interfere with IGF-I signaling and disrupt
VEGF activity in the growth plate, the study presented here
was carried out to further investigate the mechanisms of
rapamycin actions on longitudinal growth by using an
experimental young rat model.
RESULTS
Growth and nutrition
Rapamycin trough levels in rapamycin-treated animals
(RAPA) group were 20.2±1.5 ng/ml. Table 1 shows that
administration of rapamycin exerted a marked adverse effect
on longitudinal growth, as showed by significant reductions
in nose to tail-tip length gain and longitudinal bone growth
rate of RAPA rats in comparison with control animals. No
changes in weight gain, food intake, and food efficiency were
observed between the two groups.
Growth plate analysis
Epiphyseal cartilages of rapamycin-treated animals exhibited
marked alterations in proliferative and hypertrophic zones.
Bromodeoxyuridine (BrdU)-labeled chondrocytes were loca-
lized in the proliferative zones of both groups and the
percentage of labeled nuclei was significantly (Pp0.05)
higher in C (40.6±1.3%) than in RAPA (32.2±1.6%) group.
Histomorphometric analysis revealed differences in the
height of the epiphyseal cartilage, which was much higher
in RAPA group than in control animals (Table 2). These
differences were also observed in the height of the
hypertrophic zone. In addition, the height of terminal
chondrocytes was significantly lower in RAPA than in C
animals. No differences were found in the expression of
collagen type X mRNA (Figure 1a) and protein (Figure 1b),
and in alkaline phosphatase (Figure 1c).
Vascular invasion and VEGF expression
Picrosirius red/alcian blue/hematoxilin staining revealed
morphological and structural differences in the vascular
invasion front between both rats’ groups. Whereas long-
itudinal septa of C animals were well defined and parallel to
the long axis of the bone, RAPA animals exhibited a
disturbed pattern with many transverse unresorbed septa
and sinuous capillary sprouts (images not shown).
Tartrate-resistant acid phosphatase (TRAP)þ cells were
found in the primary spongiosa and along the vascular
invasion front in all groups. In the area between the chondro-
osseous junction and 50 mm deep in the primary spongiosa,
the number of TRAP-reactive cells per mm2 in RAPA samples
(198±19 TRAPþ cells/mm2) was significantly less than that
in C (356±11 TRAPþ cells/mm2). These differences were
not observed in the zone farther than 50 mm of the cartilage
distal end (C: 323±8 TRAPþ cells/mm2; RAPA: 335±25
TRAPþ positive cells/mm2).
VEGF immunohistochemical signal was localized within
the cytoplasm of hypertrophic chondrocytes from the early
hypertrophic zone to the distal end of the cartilage in C rats
(Figure 2b), whereas the terminal chondrocytes were rarely
immunopositive in rapamycin-treated animals (C: 78±4
positive cells/100 terminal chondrocytes vs RAPA: 10±1
positive cells/100 terminal chondrocytes). This pattern of
VEGF protein distribution was also observed at mRNA level
as disclosed by in situ hybridization experiments (Figure 2a).
No statistical differences were found for VEGF mRNA
levels (Figure 3a) or protein (Figure 4a) between C and RAPA
animals in the growth plate or in the kidney, and similar
hipoxia-inducible factor 1a (HIF1a) mRNA levels were also
found in both groups (Figure 3a).
Table 1 | Growth and food intake of control rats (C) and rats
treated with rapamycin (RAPA)
C (n=10) RAPA (n=10)
Weight gain (g) 51.4±2.3 49.9±2.2
Change in length (cm) 6.2±0.2 5.2±0.2a
Longitudinal growth rate (mm/day) 185±8 81±5a
Cumulative food intake (g) 215.8±6.4 217.9±6.8
Food efficiency (g/g) 0.24±0.01 0.23±0.01
Values are expressed as mean±s.e.m. Food efficiency was calculated as grams of
gained weight divided by grams of consumed food.
aMeans statistically different from C group (Pp0.05).
Table 2 | Characteristics of the growth plate of control rats (C)
and rats treated with rapamycin (RAPA)
C (n=10) RAPA (n=10)
Epiphyseal cartilage height (mm) 395±20 676±35a
Hypertrophic zone height (mm) 246±14 453±17a
Height of terminal chondrocytes (mm) 30±0 27±0a
Values are expressed as mean±s.e.m.
aMeans statistically different from C group (Pp0.05).
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GH–IGF-I axis
Circulating levels of IGF-I were significantly greater in RAPA
(680.7±78.4 ng/ml) than in C (517.4±41.1 ng/ml) animals.
Rapamycin significantly upregulated hepatic mRNA levels of
IGF-I, IGF-I receptor (IGF-IR), and GH receptor (GHR), as
shown in Figure 3b. Interestingly, no significant differences in
IGF-I, IGF-IR, and GHR mRNA levels were observed in the
growth cartilage. As shown in Figures 2c, e and g, in situ
hybridization signals for IGF-I, IGF-IR, and GHR, albeit
more intense in early hypertrophic zone, were localized in the
cytoplasm of nearly all hypertrophic chondrocytes of both
groups of rats. Similar results were observed in the
immunohistochemistry experiments for IGF-I and IGF-IR
(Figures 2d and f). Insulin-like growth factor binding protein
(IGFBP)-3 and IGFBP-5 immunohistochemical signal in
growth cartilage was confined to hypertrophic chondrocytes
and there were no differences between groups (Figure 5).
Autophagy
Autophagy was detected in liver and growth cartilage by the
presence of microtubule-associated protein light chain 3
(LC3-II) isoform (Figure 4b). Rapamycin treatment did not
increase autophagy in epiphyseal chondrocytes, whereas a
consistent increase in LC3-II/LC3-I ratio was seen in the liver
of RAPA animals, indicating an induction of the autophagic
activity in this organ.
DISCUSSION
This study confirms that administration of rapamycin at
doses that produce trough-circulating levels in the upper
range of immunosuppressive concentrations used in renal
transplantation, severely impairs the longitudinal growth
rate. This undesirable effect should be taken into account
when the drug is given to children and needs to be assessed in
pediatric clinical series. The study provides novel informa-
tion on the underlying mechanisms of growth retardation
associated with rapamycin administration. VEGF was
abnormally expressed in the growth cartilage of rapamycin-
treated rats as VEGF mRNA and peptide signals were
markedly reduced in the terminal chondrocytes sited adjacent
to the primary spongiosa. In agreement with this finding and
with the demonstrated role of VEGF as a key regulating
factor of vascular invasion of the growth plate,21 blood vessels
and septa architecture within the primary spongiosa were
profoundly disturbed by rapamycin administration. VEGF
suppression has been reported to delay osteoclast recruitment
and differentiation in the growth plate,21 which is also
consistent with the decreased number of TRAPþ cells found
in the cartilage-bone junction of rats receiving rapamycin. It
is noteworthy that these alterations were found in the
presence of unmodified total levels of growth plate VEGF and
its mRNA, as measured by western blot and real time PCR,
respectively, disclosing the critical importance of specific VEGF
expression in the terminal differentiated chondrocytes for the
normal regulation of the endochondral ossification process.
The treatment with rapamycin, the way it was administered in
our experimental model, did not impair the overall expression
of VEGF and VEGF mRNA in the kidney. These findings are
consistent with the lack of alterations found in the rapamycin-
treated rats’ mRNA levels of kidney and growth plate HIF-1a,
peptide that has been reported to be a major regulator of
VEGF expression;26 however, it is in contrast with former
studies showing VEGF downregulation by rapamycin in
cultures of tumoral or overexpressing VEGF cells22,23 and in
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Figure 1 |Collagen X (Col X) expression and alkaline
phosphatase in the growth cartilage of control and
rapamycin-treated rats (RAPA). Representative images of in situ
hybridization (a) and immunohistochemistry (b) of collagen X and
alkaline phosphatase stain (c) are shown. Bar¼ 100mm.
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Figure 2 | In situ hybridization and immunohistochemistry analysis in the growth cartilage of proximal tibiae of control and
rapamycin-treated rats (RAPA). Representative images of in situ hybridization experiments for vascular endothelial growth factor (VEGF)
(a), insulin-like growth factor I (IGF-I) (c), IGF-I receptor (IGF-IR) (e), and growth hormone receptor (GHR) (g) mRNAs, and of
immunohistochemistry experiments for VEGF (b), IGF-I (d), and IGF-IR (f) are shown. Bar¼ 100mm.
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in vivo models treated with high doses of rapamycin.10,25 This
disparity may be related to different experimental conditions,
dosage, and ways of rapamycin administration.
The present study also analyzed the effect of rapamycin
administration on the GH–IGF-I axis, a major hormonal
regulator of longitudinal growth. Circulating IGF-I concen-
trations were significantly higher in rapamycin-treated rats,
likely as a result of increased hepatic IGF-I synthesis, as IGF-I
mRNA was upregulated in this group of rats. It is noteworthy
that a positive correlation between body size and circulating
IGF-I levels has formerly been reported.27 In spite of having
higher concentrations of circulating IGF-I, rats treated with
rapamycin grew less than their controls, indicating a potential
resistance to the systemic action of IGF-I. This might result
from mTOR inhibition by rapamycin, as mTOR has been
reported to function downstream of IGFI receptor in the
IGF-I signaling pathway.9,16 It is interesting to point out that
the rapamycin’s effects were tissue dependent and the drug
did not modify the local expression of IGF-I, IGF-IR, and
GHR mRNAs in the growth plate. As IGFBP-3 and IGFBP-5
have been shown to inhibit and stimulate IGF-I action,
respectively, in cultured rat growth plate chondrocytes,28
immunohistochemical expression of these peptides was
analyzed in the growth plate of untreated and rapamycin-
treated rats without appreciating any difference. Thus, the
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Figure 3 |Quantitative PCR experiments. (a) mRNA expression
of vascular endothelial growth factor (VEGF) and HIF1a, in the
whole kidney and the growth plate of control rats (white columns)
and rats treated with rapamycin (black columns). (b) mRNA
expression of insulin-like growth factor I (IGF-I), IGF-I receptor
(IGF-IR), and growth hormone receptor (GHR) in the liver and the
growth plate of control rats (white columns) and rats treated with
rapamycin (black columns). Values are expressed as mean±s.e.m.
of gene fold-change relative to control group and normalized by
glyceraldehyde 3-phosphate expression levels. aMeans statistically
different from C group (Pp0.05).
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Figure 4 |Western blot experiments. (a) Analysis of vascular
endothelial growth factor (VEGF) in the growth cartilage and kidney
of control and rapamycin-treated rats (RAPA). (b) Analysis of LC3-I
(18 kDa) and LC3-II (16 kDa) in the growth cartilage and liver of
control (white columns) and rapamycin-treated rats (RAPA, black
columns). Data are representative of three blots giving similar
results. aMeans statistically different from control group (Pp0.05).
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Figure 5 | Immunohistochemistry analysis of insulin-like
growth factor binding proteins (IGFBPs) in the growth
cartilage of proximal tibiae of control and rapamycin-treated
rats (RAPA). Representative images of immunohistochemistry
experiments for IGFBP-3 (a) and IGFBP-5 (b) are shown.
Bar¼ 100mm.
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present study indicates that the adverse influence of
rapamycin on longitudinal growth rate and on the prolifera-
tion and maturation of chondrocytes cannot be explained by
interference with the local expression or activity of GH–IGF-I
in the growth plate. It rather suggests that rapamycin itself
was able to disturb the normal metabolism of the growth
cartilage chondrocytes and, subsequently, slow down the
longitudinal growth of treated individuals. In this regard,
Bohensky et al.29 have recently reported that mTOR
inhibition induces autophagy in cultured chondrocytes. As
autophagy is known to have a key role in chondrocyte
survival and function within the growth plate,30 it could be
argued that the alterations in chondrocyte maturation and
hypertrophy found in our rapamycin-treated animals were
due to an enhanced autophagic process. The western blot
analysis in the growth plate of LC3 (MBL International,
Woburn, MA, USA) expression, a well known marker of
autophagy, does not support this hypothesis and suggests
again that the response to rapamycin is somewhat tissue
specific (Figure 4b). Recent findings31 have shown that in
response to differential cues from mTOR, Notch serves as a
molecular switch to couple two seemingly unrelated cellular
processes: proliferation and differentiation. Interference of
this signaling mTOR/Notch pathway by rapamycin might
explain its effects on proliferation and differentiation of
growth plate chondrocytes.
In summary, this study shows the adverse effect of
rapamycin on growth and suggests for the first time that,
in association with this undesirable effect, the drug disturbs
the life cycle of growth plate chondrocytes, decreases the
expression of VEGF in the growth cartilage adjacent to the
methaphyseal bone, alters the process of vascular front
invasion, and causes a state of resistance to endogenous
IGF-I action.
ANIMALS AND METHODS
Male Sprague–Dawley rats aged 4 weeks and weighing
70±5 g were housed in individual cages under controlled
conditions of light (12 h light/dark cycle) and temperature
(21–231C). All animals received standard rat chow (A03;
Panlab, Barcelona, Spain) and tap water. The study complied
with current legislation on animal experiments in the
European Union was approved by the Ethics Committee on
Animal Research of the University of Oviedo, Spain.
Experimental protocol and sample collection
After 4 days of acclimation, animals were classified into two
groups of 10 individuals each: RAPA and control animals
pair-fed with RAPA group (C). From day 0 to day 13 of the
protocol, 1 mg/kg/day of rapamycin diluted in 5% dimethyl
sulfoxide (Sigma, St Louis, MO, USA) was administered
intraperitoneally at 1000 hours to the RAPA group, whereas
C group received vehicle (5% dimethyl sulfoxide). Animals
were killed under anesthesia on day 14 of the protocol,
approximately at the time of daily rapamycin injection. At 3
days before killing, each animal received 20 mg/kg of calcein
(Sigma) by intraperitoneal route for calculation of osseous
front advance as an index of longitudinal bone growth rate.13
BrdU (100 mg/kg; Sigma) was also injected intraperitoneally
at 1, 9, and 17 h before animals’ death. Blood samples were
collected and stored at 201C until the measurement of
rapamycin and circulating IGF-I concentrations. The whole
left kidney, a portion of liver, and the proximal end of right
tibiae were immediately frozen in liquid nitrogen for mRNA
and protein studies. Proximal ends of left tibiae were
embedded in methyl metacrilate as previously described.32
Samples from half the animals were fixed in 40% ethanol and
used for analysis of calcein and BrdU staining. The remaining
samples were fixed in 4% paraformaldehyde and used for
histomorphometry, immunohistochemistry, and in situ
hybridization studies.
Blood measures
Trough concentrations of rapamycin were measured in
whole-blood samples using an Abbott Imx analyzer (Abbott
Cientifica, Madrid, Spain) as previously described.13 IGF-I
serum concentrations were measured by enzyme-linked
immunosorbent assay using a commercial kit (Immunodiag-
nostic Systems, Boldon, UK). Inter- and intra-assay variation
coefficients were under 7%.
Growth and nutrition
Food intake and body weight were measured daily using an
electronic balance (Ohaus GT 2100, Florham Park, NJ, USA).
Nose to tail-tip length was measured under anesthesia on
days 0 and 14. Food efficiency was calculated as the ratio
between weight gained and food consumed (g/g) by each
animal between days 0 and 14 of the protocol. Longitudinal
growth rate was measured in 10 mm-thick frontal sections of
the proximal end of tibiae as described elsewhere.32
Growth plate histology and histomorphometry
Frontal sections (5 mm thick) of proximal tibiae fixed in
formalin were stained by the following methods: alcian blue/
safranine (Merck, Darmstadt, Germany) for morphometric
analysis, alkaline phosphatase stain (Roche, Basel, Switzerland)
for chondrocyte maturation, TRAP stain (Sigma) for
osteoclast identification, and picrosirius red/alcian blue/
hematoxylin (Merck) for analysis of bone and cartilage
extracellular matrix. Heights of the growth cartilage and its
hypertrophic zone were identified following morphological
criteria and measured at regular intervals using an image
analysis system described elsewhere.13 Height of the three most
distal hypertrophic chondrocytes was measured in alternate
columns using the same system. The number of TRAPþ cells
at the vascular invasion front was measured in two different
zones: an area extending 50mm from the distal end of the
growth cartilage into the primary spongiosa, and another
area immediately below extending from 50 to 150mm
of the chondro-osseus union. Two slides per animal were
used and results were expressed as the number of positive
cells per mm2.
566 Kidney International (2010) 78, 561–568
or ig ina l a r t i c l e O´ A´lvarez-Garcı´a et al.: Rapamycin disrupts growth plate angiogenesis
Growth plate immunohistochemistry and in situ hybridization
Immunodetection of BrdU, IGF-I, IGF-IR, IGFBP-3, IGFBP-5,
and VEGF were carried out as described elsewhere.32,33 Two
sections per animal were analyzed. The proliferating activity
was expressed as the number of positive cells per 100 cells in
the proliferative zone, previously defined as the band of tissue
between the resting zone and a line traced by the most distal
BrdU-labeled cells. VEGF immunohistochemical signal was
measured in the three most distal chondrocytes and
expressed as number of positive cells per 100 terminal
chondrocytes.
In situ hybridization was used to define the mRNA
distribution pattern of VEGF, collagen type X, IGF-I, IGF-R
and GHR in the growth cartilage following a methodology
previously described.33 RNA probes were supplied by
GeneDetect (Auckland, New Zealand). One section per
animal was hybridized with a labeled sense riboprobe and a
second section was incubated adding a negative control probe
to the hybridization mixture. Two sections served as negative
controls.
Real-time PCR
mRNA was extracted from frozen liver, kidney, and tibiae
samples using a modified Chomczynski method.34 Samples
were diluted to 1mmol/l per ml concentration before retro-
transcription with a commercial kit (Qiagen Iberia, Madrid,
Spain). RNA purity was assessed by 260/280 ratio measure-
ment using a ultraviolet spectrophotometer (GeneQuant Pro,
Amersham Biosciences, GE Healthcare Spain, Barcelona,
Spain). VEGF, HIF1a, IGF-I, IGF-R, and GHR expression was
quantified by real-time PCR on a sequence detection system
step one (Applied Biosystems, Foster City, CA, USA) with SYBR
Green (ABgene Products, Thermo Fisher Scientific, Rockford,
IL, USA) as fluorophore and glyceraldehyde 3-phosphate as
a housekeeping gene. Oligonucleotide primer pairs were as
follows: for VEGF forward CGTCCAATTGAGACCATGGT
and reverse TCCGCATGATCTGCATAGTGA; for IGF-I for-
ward TACCAGCTCGGCCACAGC and reverse GTGGGCTT
GTTGAAGTAAAAGC; for IGF-R forward GCTGCTGGACC
ACAAATCG and reverse TCGCTTCCCACACACACTTG;
and for GHR forward AATTAATCCAAGCCTGAGGGAAA
and reverse GGAACGACACTTGGTGAATCG. Primer se-
quences were designed with the Prime Express software
(Perkin-Elmer Applied Biosystems) and synthesized by
Invitrogen (Fisher–Invitrogen, Barcelona, Spain) whereas
glyceraldehyde 3-phosphate and HIF1a primers were synthe-
sized and supplied by Qiagen (Qiagen Iberia).
Western blot
Frozen kidney, liver, and tibia samples were homogenized in a
lysis buffer containing 1 M Tris pH 7.4, 0.1% Triton X-100,
500 mM EDTA, 300 mM saccharose, and a protease inhibitor
tablet (Sigma). The cytosolic fraction was collected as a
supernatant after centrifugation at 12,000 g for 10 min at 41C.
A total of 50 mg of protein were resolved in 4–20% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and trans-
ferred to polyvinylidene difluoride membrane (Immobilon-
P; Millipore Iberica, Madrid, Spain). The membranes were
blocked in 5% (w/v) non-fat dry milk in TBST (Tris-buffered
saline, pH 7.4, containing 0.05% Tween 20) at room
temperature for 1 h. After blocking, blots were incubated
with primary rabbit antibody specific to VEGF (Neo
Markers, Westinghouse, CA, USA) or LC3 diluted 1:500 in
TBST at 41C overnight. Immunoblots were washed three
times with TBST and incubated at room temperature for 1 h
with the secondary antibody (En Vision; Dako Diagnosticos
SA, Barcelona, Spain) diluted 1:5000 in TBST. Peroxidase
activity was visualized using a chemiluminescent HRP
substrate commercial kit (Immobilon Western; Millipore
Iberica) following manufacturer’s instructions.
Statistical analysis
Data are given as mean±s.e.m.. Significant differences with
the control group were determined by the Student t-test. A
P-value p0.05 was considered significant. All data sets were
analyzed using SPSS 15.0 software package (SPSS, Chicago,
IL, USA).
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